Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CTSC | P53634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15113167 | 0.77 | PIK3CD (0.61) | PIK3CD | |
| SCHEMBL13218352 | 0.77 | PIK3CD (0.61) | PIK3CDPOLB | |
| SCHEMBL8435737 | 0.77 | PIK3CD (0.61) | PIK3CDPOLB | |
| SCHEMBL27735477 | 0.77 | CYP1A2 (0.39) | PIK3CDCYP1A2CYP3A4RECQLMAPK1 | |
| SCHEMBL27735475 | 0.77 | CYP1A2 (0.39) | PIK3CDCYP1A2CYP3A4RECQLMAPK1 | |
| SCHEMBL15768041 | 0.76 | PIK3CD (0.59) | PIK3CDMAPK1POLB | |
| SCHEMBL1687263 | 0.75 | — | — | |
| SCHEMBL21141432 | 0.75 | PIK3CD (0.36) | PIK3CDCYP1A2CYP3A4RECQLMAPK1 | |
| SCHEMBL13218345 | 0.74 | PIK3CD (0.57) | PIK3CDMAPK1 | |
| SCHEMBL12308386 | 0.74 | CYP1A2 (0.37) | PIK3CDCYP1A2CYP3A4RECQLMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021444-B2 | Antiviral compounds | Janssen Biopharma, Inc. (US) | 2021-06-01 | — | — | US | disclosed |
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2019-08-29 | — | — | US | disclosed |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. | 2018-03-08 | — | — | US | disclosed |
| CN-1043700-A | The compound that is used for the treatment of the urinary incontinence | PHARMACIA AB (SE) | 1990-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263754-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PIK3CD 2204/4885CYP1A2 4754/4885CYP3A4 3687/4885 |
| US-11021444-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | PIK3CD 2204/4885CYP1A2 4754/4885CYP3A4 3687/4885 |
| US-20180065932-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | PIK3CD 2204/4885CYP1A2 4754/4885CYP3A4 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.